SD
Sandy Draper Guggenheim Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Medpace
MEDP
$13.7B
| $486.98 | $432 |
11%
downside
| Buy | 1 year ago |
|
2
Evolent Health
EVH
$1.11B
| $9.61 | $34 |
254%
upside
| Hold | 1 year ago |
|
|
3
Evolent Health
EVH
$1.11B
| $9.61 | $47 |
389%
upside
| Buy | 2 years ago |
|
4
GoodRx Holdings
GDRX
$1.39B
| $4 | $10 |
150%
upside
| Buy | 2 years ago |
|
5
The Oncology Institute
TOI
$309M
| $3.30 | $2 |
39%
downside
| Buy | 2 years ago |
|
6
Icon
ICLR
$13.6B
| $174.88 | $263 |
50%
upside
| Buy | 2 years ago |
|
7
Agilon Health
AGL
$497M
| $1.20 | $30 |
2,400%
upside
| Buy | 2 years ago |
|
8
HealthEquity
HQY
$7.88B
| $91.48 | $94 |
3%
upside
| Buy | 2 years ago |
|
9
Privia Health
PRVA
$2.86B
| $23.28 | $51 |
119%
upside
| Buy | 3 years ago |
|
10
Natera
NTRA
$23.1B
| $168.02 | $129 |
23%
downside
| Buy | 4 years ago |
|
11
Charles River Laboratories
CRL
$8.07B
| $163.99 | $369 |
125%
upside
| Buy | 4 years ago |
|
12
Veracyte
VCYT
$2.55B
| $32.43 | $55 |
70%
upside
| Buy | 4 years ago |
|
13
Exact Sciences
EXAS
$10.2B
| $53.81 | $168 |
212%
upside
| Buy | 4 years ago |
|
|
14
Agilon Health
AGL
$497M
| $1.20 | $40 |
3,233%
upside
| Buy | 4 years ago |
|
15
IQVIA
IQV
$31.9B
| $187.68 | $260 |
39%
upside
| Buy | 4 years ago |
|
16
Hims & Hers Health
HIMS
$10.9B
| $48.41 | $12 |
75%
downside
| Hold | 4 years ago |
|
|
17
Icon
ICLR
$13.6B
| $174.88 | $280 |
60%
upside
| Buy | 4 years ago |
|
|
18
Medpace
MEDP
$13.7B
| $486.98 | $180 |
63%
downside
| Buy | 4 years ago |
|
19
Premier
PINC
$2.13B
| $25.85 | $38 |
47%
upside
| Hold | 4 years ago |
|
20
Personalis
PSNL
$465M
| $5.24 | $50 |
854%
upside
| Buy | 4 years ago |
|
21
NeoGenomics
NEO
$1.03B
| $7.98 | $65 |
715%
upside
| Buy | 4 years ago |
|
|
22
Evolent Health
EVH
$1.11B
| $9.61 | $15 |
56%
upside
| Buy | 5 years ago |
|
23
Teladoc Health
TDOC
$1.38B
| $7.82 | $200 |
2,458%
upside
| Hold | 5 years ago |
|
|
24
Premier
PINC
$2.13B
| $25.85 | $32 |
24%
upside
| Hold | 5 years ago |
|
|
25
Charles River Laboratories
CRL
$8.07B
| $163.99 | $194 |
18%
upside
| Buy | 5 years ago |
|